{"id":"mepolizumab-sc","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Upper respiratory tract infections"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-5 is a key cytokine responsible for eosinophil development, recruitment, and survival. By blocking IL-5, mepolizumab reduces circulating and tissue eosinophil levels, thereby decreasing eosinophil-mediated inflammation. This mechanism is particularly effective in eosinophil-driven diseases such as severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA).","oneSentence":"Mepolizumab is a monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), reducing eosinophil production and activation in the immune system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:50.152Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe eosinophilic asthma"},{"name":"Eosinophilic granulomatosis with polyangiitis (EGPA)"},{"name":"Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype)"}]},"trialDetails":[{"nctId":"NCT04157348","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-10-29","conditions":"Eosinophilic Granulomatous Vasculitis","enrollment":140},{"nctId":"NCT05091385","phase":"","title":"Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma","status":"COMPLETED","sponsor":"Medical University of Lodz","startDate":"2022-01-01","conditions":"Asthma; Eosinophilic","enrollment":106},{"nctId":"NCT06477653","phase":"PHASE2","title":"Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-02-05","conditions":"Hypereosinophilic Syndrome","enrollment":30},{"nctId":"NCT04965636","phase":"PHASE3","title":"Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-07-11","conditions":"Hypereosinophilic Syndrome","enrollment":16},{"nctId":"NCT04133909","phase":"PHASE3","title":"Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-10-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":806},{"nctId":"NCT05902325","phase":"PHASE4","title":"Identifying Predictors Of Response To Mepolizumab In CRSwNP","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2023-10-03","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":36},{"nctId":"NCT04276233","phase":"PHASE4","title":"Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-06-29","conditions":"Asthma","enrollment":100},{"nctId":"NCT04607005","phase":"PHASE3","title":"Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)/ Eosinophilic Chronic Rhinosinusitis (ECRS)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-04-22","conditions":"Nasal Polyps","enrollment":169},{"nctId":"NCT04305678","phase":"PHASE1","title":"Mepolizumab for Eosinophilic Fasciitis","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2023-02","conditions":"Eosinophilic Fasciitis","enrollment":""},{"nctId":"NCT03028480","phase":"","title":"Long Term Special Drug Use Investigation of Mepolizumab","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-11","conditions":"Asthma","enrollment":1061},{"nctId":"NCT04183192","phase":"PHASE1","title":"Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2020-02-17","conditions":"Healthy Subjects, Pharmacokinetics, Pharmacodynamics","enrollment":72},{"nctId":"NCT05642806","phase":"PHASE4","title":"Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment","status":"RECRUITING","sponsor":"St. Paul's Sinus Centre","startDate":"2023-07-01","conditions":"Chronic Rhinosinusitis With Nasal Polyps, Asthma, Chronic Rhinosinusitis Without Nasal Polyps","enrollment":90},{"nctId":"NCT03298061","phase":"PHASE3","title":"Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-04-14","conditions":"Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis","enrollment":100},{"nctId":"NCT03099096","phase":"PHASE3","title":"Study of Mepolizumab Autoinjector in Asthmatics","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-05-04","conditions":"Asthma","enrollment":159},{"nctId":"NCT01691859","phase":"PHASE3","title":"MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-09-28","conditions":"Asthma","enrollment":347},{"nctId":"NCT03085797","phase":"PHASE3","title":"Effect of Mepolizumab in Severe Bilateral Nasal Polyps","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-05-25","conditions":"Nasal Polyps","enrollment":414},{"nctId":"NCT03306043","phase":"PHASE3","title":"A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-11-13","conditions":"Hypereosinophilic Syndrome","enrollment":102},{"nctId":"NCT02836496","phase":"PHASE3","title":"Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-03-07","conditions":"Hypereosinophilic Syndrome","enrollment":108},{"nctId":"NCT02555371","phase":"PHASE3","title":"Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-01-07","conditions":"Asthma","enrollment":306},{"nctId":"NCT04228588","phase":"PHASE4","title":"A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-01-09","conditions":"Eosinophilic Asthma","enrollment":18},{"nctId":"NCT02135692","phase":"PHASE3","title":"A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-05-29","conditions":"Asthma","enrollment":339},{"nctId":"NCT03014674","phase":"PHASE3","title":"A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-06","conditions":"Asthma","enrollment":246},{"nctId":"NCT02654145","phase":"PHASE4","title":"Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-03-17","conditions":"Asthma","enrollment":145},{"nctId":"NCT03021304","phase":"PHASE3","title":"Study of Mepolizumab Safety Syringe in Asthmatics","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-02-01","conditions":"Asthma","enrollment":56},{"nctId":"NCT02105948","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":837},{"nctId":"NCT02105961","phase":"PHASE3","title":"Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-24","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":674},{"nctId":"NCT02281318","phase":"PHASE3","title":"Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-12-11","conditions":"Asthma","enrollment":556},{"nctId":"NCT01691521","phase":"PHASE3","title":"Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-08","conditions":"Asthma","enrollment":580},{"nctId":"NCT01842607","phase":"PHASE3","title":"A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-05-27","conditions":"Asthma","enrollment":651},{"nctId":"NCT02020889","phase":"PHASE3","title":"A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-05","conditions":"Churg-Strauss Syndrome","enrollment":136},{"nctId":"NCT02594332","phase":"PHASE3","title":"Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study","status":"TERMINATED","sponsor":"Johannes Gutenberg University Mainz","startDate":"2015-11-17","conditions":"Asthma","enrollment":29},{"nctId":"NCT01366521","phase":"PHASE2","title":"Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02","conditions":"Asthma","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Mepolizumab SC","genericName":"Mepolizumab SC","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mepolizumab is a monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), reducing eosinophil production and activation in the immune system. Used for Severe eosinophilic asthma, Eosinophilic granulomatosis with polyangiitis (EGPA), Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}